Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression

NCT07670026 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Sintilimab
DRUG: Bevacizumab
RADIATION: Postoperative Radiotherapy
DRUG: Temozolomide

Sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine